Methods of treatment with finerenone
OwnerThomas EISSING, Patrick SCHLOEMER +2inventors
InventorsThomas EISSING, Patrick SCHLOEMER, Achim FRITSCH, Thomas WENDL
Life of this patent
Estimating the term…
Abstract
The disclosure refers to a method of preventing or treating heart failure in a patient using (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide (INN: Finerenone)
Claims30
A method of coadministering finerenone with a strong CYP3A4 inhibitor to a patient in need thereof, comprising administering about 10-60% of a target daily dose of finerenone recommended for an otherwise similar patient who is not co-administered the strong CYP3A4 inhibitor.
A method of initiating finerenone treatment in a patient in need thereof that is currently treated with a strong CYP3A4 inhibitor, comprising administering about 10-60% of a starting daily dose of finerenone recommended for an otherwise similar patient who is not co-administered the strong CYP3A4 inhibitor.
A method of reducing the risk of a comorbidity of heart failure in a patient treated with a strong CYP3A4 inhibitor and in need of treatment with finerenone, comprising administering about 10-60% of a target daily dose of finerenone recommended for an otherwise similar patient who is not co-administered the strong CYP3A4 inhibitor.
Dependencies are inferred from the claim text.